GlassScriptPhysician profile
Sean Ian Sanchez
NPI 1225207186
$1,280.90
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.61 · 2021: $446 · 2022: $231 · 2023: $277 · 2024: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $229.42 | 2021-2024 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $199.94 | 2019-2023 | Jynarque |
| Abbott Laboratories | $169.72 | 2023 | Cardiomems |
| Novo Nordisk INC | $166.83 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Ardelyx, INC. | $124.99 | 2024 | Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $83.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.58 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $73.27 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.